Immatics Announces Annual General Meeting for June 2025

The latest announcement is out from Immatics ( (IMTX) ).

On June 2, 2025, Immatics N.V. announced the convening of its annual general meeting, scheduled for June 18, 2025, in Amsterdam, Netherlands. This meeting will allow shareholders to discuss and vote on various company matters, reflecting Immatics’ commitment to maintaining transparency and active shareholder engagement. The announcement underscores the company’s ongoing efforts to align its governance practices with shareholder interests, potentially impacting its strategic direction and stakeholder relations.

The most recent analyst rating on (IMTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.

Spark’s Take on IMTX Stock

According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.

Immatics’ stock score is influenced by strong revenue growth but offset by profitability and cash flow challenges. Technical analysis suggests moderate short-term bullish momentum, though longer-term trends remain bearish. Valuation struggles with a negative P/E ratio, common in the biotech industry.

To see Spark’s full report on IMTX stock, click here.

More about Immatics

Immatics N.V. is a biotechnology company based in Tübingen, Germany, focusing on the development of T-cell receptor-based cancer immunotherapies. The company operates within the biopharmaceutical industry, aiming to deliver innovative treatments for cancer patients by leveraging its proprietary technology platforms.

Average Trading Volume: 658,755

Technical Sentiment Signal: Sell

Current Market Cap: $655.2M

For detailed information about IMTX stock, go to TipRanks’ Stock Analysis page.